Diagnosis and management of oral mucositis

Journal of Supportive Oncology

Volumn 5, Issue 2 SUPPL. 1, 2007, Pages 13-21

  Silverman Jr , Sol ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AES 14; AMIFOSTINE; AMPHOTERICIN B; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; BENZYDAMINE; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PACLITAXEL; PALIFERMIN; PLACEBO; POLYMYXIN; SAFORIS; TOBRAMYCIN; UNCLASSIFIED DRUG;

ARTHRALGIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COST OF ILLNESS; CRYOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSESTHESIA; DYSGEUSIA; EDEMA; ERYTHEMA; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HOSPITALIZATION; HUMAN; HYPOTENSION; INCIDENCE; INFECTION; LARYNX CANCER; MOUTH HYGIENE; MOUTH PAIN; MOUTH TUMOR; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; ORAL MUCOSAL DISEASE; OROPHARYNX TUMOR; PATHOGENESIS; RADIATION EXPOSURE; RADIATION PROTECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SOLID TUMOR; STEM CELL TRANSPLANTATION; THRUSH; TONGUE DISEASE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

HUMANS; MUCOSITIS;

EID: 33847351783     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther 2003;18:853-874.
2. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253-262.
3. Peterson DE. New strategies for management of oral mucositis in cancer patients. J Support Oncol 2006;4(suppl 1):9-13.
4. Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer 2006;107:2525-2534.
5. Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-39.
6. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205.
7. Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999;17:2446-2453.
8. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-1539.
9. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-284.
10. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis 2006;12:229-241.
11. Tang IT, Shepp DH. Herpes simplex virus infection in cancer patients: prevention and treatment. Oncology (Williston Park) 1992;6:101-106, 109.
12. Khan SA, Wingard JR. Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr 2001;29:31-36.
13. Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005;11:383-388.
14. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 1999;85:2103-2113.
15. Sonis ST, Elting LS, Keefe D, et al; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100(9 suppl):1995-2025.
16. Rubenstein EB, Peterson DE, Schubert M, et al; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100(suppl):2026-2046.
17. McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer 2006;14:541-547.
18. Ship JA, Eisbruch A, D'Hondt E, Jones RE. Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: one-year results. J Dent Res 1997;76:807-813.
19. Perch SJ, Machtay M, Markiewicz DA, Kligerman MM. Decreased acute toxicity by using midline mucosa-sparing blocks during radiation therapy for carcinoma of the oral cavity, oropharynx, and nasopharynx. Radiology 1995;197:863-866.
20. Mantini G, Manfrida S, Cellini F, et al. Impact of dose and volume on radiation-induced mucositis. Rays 2005;30:137-144.
21. Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/ IV head and neck cancer. Semin Oncol 2003;30(suppl 18):40-48.
22. Stokman MA, Spijkervet FKL, Boezen HM, et al. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 2006;85:690-700.
23. Grdina DJ, Kataoka Y, Murley JS. Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metab Drug Interact 2000;16:237-279.
24. Stokman MA, Wachters FM, Koopmans P, et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis: a phase II study. Anticancer Res 2004;24:3263-3267.
25. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:739-747.
26. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-3345.
27. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006;64:784-791.
28. Blonder J, Etter J, Samaniegoet A, et al. Topical bioadhesive antioxidants reduce the severity of experimental radiation induced oral mucositis. Proc Am Soc Clin Oncol 2001;20:1606.
29. Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCI for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled trial. Cancer 2001;92:875-885.
30. Kannan V, Bapsy PP, Anantha N, et al. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys 1997;37:1005-1010.
31. Tejedor M, Valerdi JJ, Arias F, et al. Hyperfractionated radiotherapy concomitant with cisplatin and granulocyte colony-stimulating factor (filgrastim) for laryngeal carcinoma. Cytokines Cell Mol Ther 2000;6:35-39.
32. McAleese JJ, Bishop KM, A'Hern R, Henk JM. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. Br J Radiol 2006;79:608-613.
33. Masucci G, Broman P, Kelly C, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Med Oncol 2005;22:247-256.
34. Dazzi C, Cariello A, Giovanis P, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann Oncol 2003;14:559-563.
35. Karthaus M, Rosenthal C, Huebner G, et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-785.
36. Mascarin M, Franchin G, Minatel E, et al. The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol 1999;35:203-208.
37. Antin JH, Lee SJ, Neuberg D, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 2002;29:373-377.
38. Smith JW 2nd. Tolerability and side-effect profile of rhIL-11. Oncology (Williston Park) 2000;14(suppl 8):41-47.
39. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2006; advance access published on October 9, 2006; doi:10.1093/annonc/mdl332.
40. Borges L, Rex KL, Chen JN, et al. A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. Int J Radiat Oncol Biol Phys 2006;66:254-262.
41. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006:24:5194-5200.
42. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-2598.
43. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186-5193.
44. Siddiqui MA, Wellington K. Palifermin: in myelotoxic therapy-induced oral mucositis. Drugs 2005;65:2139-2146.
45. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003;29:501-513.
46. Cockerham MB, Weinberger BB, Lerchie SB. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 2000;34:300-303.
47. Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Safaris for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109:322-331.